Łukaszewicz-Zając Marta, Pączek Sara, Mroczko Piotr, Kulczyńska-Przybik Agnieszka
Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland.
Department of Criminal Law and Criminology, Faculty of Law, University of Bialystok, Bialystok, Poland.
Cancer Manag Res. 2020 Sep 14;12:8435-8443. doi: 10.2147/CMAR.S267176. eCollection 2020.
Every year, almost 2 million people develop colorectal cancer (CRC), which makes it the fourth most common malignancy worldwide. It is also estimated that approximately 48% of CRC patients will die from the disease. Thus, noninvasive and accurate methods for early detection and prevention of CRC are sorely needed. It is suggested that C-X-C motif ligand 1 (CXCL1) and C-X-C motif ligand 8 (CXCL8) as well as their cognate receptors can mediate tumor growth, proliferation, survival, neoangiogenesis and metastasis of malignant cells, including CRC. However, little is known about the clinical significance of these proteins as potential biomarkers for CRC. Therefore, in our review, we performed a comprehensive literature search using the PubMed database to identify original articles that investigated whether CXCL1 and CXCL8 and their receptors play a role in CRC pathogenesis. In summary, our review highlighted the potential significance of CXCL1/CXCR2 and CXCL8/CXCR1,-2 in the diagnosis and progression of CRC as well as indicated their potential therapeutic significance. However, given the non-specific nature of analyzed chemokines and a small number of studies concerning the assessment of blood concentration of these proteins in CRC patients, investigations need to be continued in the future before selected chemokines could be established as biomarkers for CRC.
每年，近200万人罹患结直肠癌（CRC），这使其成为全球第四大常见恶性肿瘤。据估计，约48%的结直肠癌患者将死于该疾病。因此，迫切需要用于早期检测和预防结直肠癌的非侵入性且准确的方法。有人提出，C-X-C基序配体1（CXCL1）和C-X-C基序配体8（CXCL8）以及它们的同源受体可介导包括结直肠癌在内的恶性细胞的肿瘤生长、增殖、存活、新生血管生成和转移。然而，对于这些蛋白质作为结直肠癌潜在生物标志物的临床意义知之甚少。因此，在我们的综述中，我们使用PubMed数据库进行了全面的文献检索，以识别研究CXCL1和CXCL8及其受体是否在结直肠癌发病机制中起作用的原始文章。总之，我们的综述强调了CXCL1/CXCR2和CXCL8/CXCR1、-2在结直肠癌诊断和进展中的潜在意义，并指出了它们的潜在治疗意义。然而，鉴于所分析趋化因子的非特异性以及关于评估结直肠癌患者血液中这些蛋白质浓度的研究数量较少，在选定的趋化因子被确立为结直肠癌的生物标志物之前，未来仍需继续进行研究。
